Drug Profile
BYON 3521
Alternative Names: BYON-3521Latest Information Update: 24 May 2023
Price :
$50
*
At a glance
- Originator Syntarga
- Developer Byondis
- Class Antineoplastics; Drug conjugates; Monoclonal antibodies
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Apr 2023 Efficacy and adverse events data from a phase I trial in solid tumours presented at the at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 13 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer released by Byondis
- 03 Aug 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Netherlands and Italy (IV) (NCT05323045)